-

Biogennix Celebrates a Decade of Innovation and Clinical Success

IRVINE, Calif.--(BUSINESS WIRE)--Irvine-based Biogennix, an advanced osteobiologics company that develops, manufactures, and distributes proprietary bone graft products used for bone fusion procedures, is celebrating the 10th anniversary of its first clinical case.

In 2011, Biogennix introduced its novel osteoSPAN™ fusion kits, which consist of two uniquely-sized porous blocks designed to “span” the transverse processes during single-level spine fusion procedures. The osteoSPAN fusion kits remain a unique offering for spine fusion procedures today.

With surgeons embracing the ease of use and clinical outcomes of osteoSPAN fusion kits, Biogennix grew exponentially and over the years has continued introducing new and novel products, including osteoSPAN granules, Morpheus® moldable bone graft, and later the collagen-enhanced Agilon® Moldable product line. Through the COVID-19 pandemic, the company continued investing in new product development and introduced its first strip product, Agilon Strip, in April of this year.

The steady success and year-over-year increases of Biogennix’s sales have led to consistent growth for the company, which continues to invest in research and development, and distributor partnerships. The company, which initially focused on spine procedures, has seen steady growth in additional market segments, most notably with foot and ankle surgeons, who are drawn to the company’s solid track record of clinical success and excellent product handling.

“It’s been a highly rewarding ten years of seeing positive clinical outcomes and receiving enthusiastic feedback from surgeons for each of our products,” said Dr. Edwin Shors, President of Biogennix. “As we enter our second decade of clinical innovation, our focus is to continue investing in new product development, strategic partnerships across the US, and manufacturing to keep up with growing demand and so that we can continue to provide new solutions for surgeons.”

Biogennix designs, manufactures and distributes all of its products from its Irvine-based facilities.

Biogennix® is a fully-integrated osteobiologics company headquartered in Irvine, CA which develops, manufactures, and distributes proprietary bone grafting products used in bone fusion procedures. Biogennix is committed to advancing technology behind next-generation bone grafting solutions, delivering outstanding quality with exceptional value, and customer-focused excellence. Learn more at biogennix.com.

Contacts

Paul Williams, 310-569-0023, paul@medialinecommunications.com

Biogennix


Release Summary
Irvine-based Biogennix, an advanced osteobiologics company, is celebrating the 10th anniversary of its first clinical case.
Release Versions

Contacts

Paul Williams, 310-569-0023, paul@medialinecommunications.com

Social Media Profiles
More News From Biogennix

Biogennix Launches Agilon Surgical Matrix

IRVINE, Calif.--(BUSINESS WIRE)--Biogennix, an osteobiologics company specializing in innovative healing solutions for surgical procedures, has announced the launch of its new Agilon Surgical Matrix wound care product. Agilon Surgical Matrix is a wound care solution derived from 100% bovine Type 1 collagen. Upon contact with a new or open wound, whether surgically or naturally occurring, Agilon Surgical Matrix transforms into a gel, enveloping the entire wound area. This coverage maintains a lo...

Biogennix Announces Publication of a Scientific Study on Its Advanced Bone Graft Technology

IRVINE, Calif.--(BUSINESS WIRE)--Biogennix, an osteobiologics company specializing in products for bone graft procedures, has announced the publication of a detailed scientific study characterizing multiple advanced properties of its TrelCor bone graft material. TrelCor is an innovative dual-phase bone graft featuring a nanocrystalline hydroxycarbanoapatite (HCA) surface, specially engineered for bone formation. The study, titled “Characterization of an Advanced Bone Graft Material with a Nanoc...

Biogennix Receives FDA Clearance for Expanded Use of Agilon Moldable and Morpheus Moldable Products

IRVINE, Calif.--(BUSINESS WIRE)--Irvine-based Biogennix, LLC an osteobiologics company specializing in bone graft products for fusion procedures, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an expanded indication for its Agilon Moldable and Morpheus Moldable bone grafting products. The new clearance allows the products to be used in the intervertebral disc space as an autograft extender, with an FDA-cleared intervertebral body fusion device...
Back to Newsroom